Sydney, Feb 24, 2026, 00:21 AEDT — The market is shut.
- Telix shed 7.9% Monday, swinging between A$9.51 and A$10.89 during the session.
- Traders are still digesting the company’s updated outlook, along with those fresh pipeline spending plans.
- Focus turns to management’s appearances at U.S. investor conferences, set to begin later this week and running into early next week.
Telix Pharmaceuticals finished Monday down 7.9%, settling at A$9.61. Shares had surged to A$10.89 right after the open, but selling pressure reversed those gains before the close. (Investing)
Why does it matter? Telix has become one of those heavily trafficked ASX stocks. A lot of investors are counting on the company’s U.S. imaging arm to come through. But the stock’s been volatile—shares can lurch if timelines shift or spending patterns look shaky.
Trading is on hold for now, so attention shifts to Telix’s top brass. Chief executive Christian Behrenbruch heads into a fireside chat at Oppenheimer on Feb. 27 (AEDT). Then, just a few days later, he’s scheduled to appear alongside Precision Medicine CEO Kevin Richardson at TD Cowen on March 3 (AEDT). (GlobeNewswire)
Telix’s latest annual report showed 2025 revenue reaching US$803.8 million. For 2026, the company is projecting group revenue in a range of US$950 million to US$970 million, while setting pipeline R&D outlays at US$200 million to US$240 million. CEO Behrenbruch said the plan is to “reinvest earnings” to speed along a pipeline now in pivotal trials, with further product launches on the horizon. (Announcements ASX)
The update laid out two main regulatory steps: a marketing authorisation application (MAA) is being filed in Europe for TLX101-Px (Pixclara), while a U.S. New Drug Application (NDA) is also moving ahead. For TLX250-Px (Zircaix), Telix said it’s close to wrapping up the requirements for a U.S. Biologics License Application (BLA) resubmission. That includes evidence showing “comparability” between clinical trial lots and production-scale material — a hurdle that often crops up if manufacturing gets tweaked. (Announcements ASX)
By the numbers, things look steadier. Telix pointed to increased Illuccix volumes and noted Gozellix’s U.S. launch. Gross margin stuck at 64%, which stands out given ongoing spending on trials and manufacturing. (Announcements ASX)
Risks are evident—regulatory holdups still loom, and fresh FDA questions about resubmissions or manufacturing specifics might force investors to rethink launch timelines. The company has already pointed to these unknowns, warning that regulatory decisions, competitor moves, and manufacturing issues could all shift the outlook. (Announcements ASX)
On Tuesday, traders are zeroed in on whether the stock manages to stay above Monday’s low. Volume is in focus after that sharp reversal earlier in the session.
Eyes shift to two upcoming conferences — Feb. 27 (AEDT) and March 3 (AEDT) — that could prove decisive. Investors are zeroed in on details around U.S. filing dates, which assets will launch first, and the scale of Telix’s spending plans for its pipeline. (GlobeNewswire)
